> About the VALOR trial
VALOR is an ongoing randomized, observer-blind, placebo-controlled Phase 3 trial which has enrolled 9,437* participants 5 years of age and older to receive VLA15 or a saline placebo (1:1 ratio). As part of the primary series, participants receive three doses of VLA15 within the first year at months 0, 2 and 5-9, and one booster dose 9-12 months after completion of the primary immunization.5 The final primary series vaccination for participants occurs just before the peak Lyme disease season for the region. Participants will be followed for the occurrence of Lyme disease. The trial is conducted at sites located in areas where Lyme disease is highly endemic across the U.S., Canada and Europe and has enrolled volunteers with a cleared past infection with Borrelia burgdorferi as well as Borrelia burgdorferi naïve volunteers.
There is lab data suggesting an interaction between LYMErix and certain genotypes potentially inducing arthritis, but the initial trial and post market surveillance data did not show any meaningfully elevated arthritis rates. However, post market surveillance was definitely hampered by the limited market uptake, fueled partly by the side effect concern.
Genetic testing/screening should be significantly cheaper today, and the higher prevalence of ticks as a concern would probably mean that LYMErix could probably be a viable product today, even if its arthritis side effect profile was real, as long as it was combined with screening.
It was around the time when vaccine and Autism mania was at its peak:
> Despite the lack of evidence that the complaints were caused by the vaccine, sales plummeted and LYMErix was withdrawn from the U.S. market by GlaxoSmithKline in February 2002, in the setting of negative media coverage and fears of vaccine side effects. The fate of LYMErix was described in the medical literature as a "cautionary tale"; an editorial in Nature cited the withdrawal of LYMErix as an instance in which "unfounded public fears place pressures on vaccine developers that go beyond reasonable safety considerations." The original developer of the OspA vaccine at the Max Planck Institute told Nature: "This just shows how irrational the world can be ... There was no scientific justification for the first OspA vaccine LYMErix being pulled.
I, too, tried to load it up today and realized it looks no longer. A search for if it existed anymore brought me here. I would have thought it's retirement would have been larger news or maybe I'm just out of the loop.
I went through them for the first time last year, without ever having seen them. I think I'd be equally excited either way. Working, I didn't get to appreciate them from the other angle, I assume equally as neat.
"I bought the fridge so my wife could keep up with my calendar. I hope this gets fixed soon. That is a lot of wasted money if no one can use this anymore."
If only there were other ways of checking or sharing an electronic calendar! The future is now.
No need to even glue. They sell things like "FridgePad - Magnetic Refrigerator Mount for iPad" that is what it says. Magnets that hold an iPad (Mini or full) to a standard fridge. You can also get 3M mounted ones which allow you to slip in an iPad.
Typically it is cheaper to buy a regular fridge and add an iPad than a smart fridge.
Also it is cheaper to buy four(!) iPads and back-seat tablet holder for a minivan than an integrated DVD player. Easier to replace when it dies too. Those DVD players can easily run $1500+.
It turns out that the high-end stainless steel fridges actually have ferrous metal components that enable the use of magnets. It's only the mid-tier stainless steel ones that are non-magnetic. (Source: research for a product launched last year which includes a fridge-mountable magnetic remote)
Those don't fit an iPad, and if you try to make it fit, you'll invalidate the warranty. You'll have to buy the special ones that fit iPads, at the Apple store. 50 dollars. Per strip.
I'm thinking that if you're in the market for a $3600 Internet-connected fridge, you can afford and would just rather have the iPad.
I don't know enough about the Fire to say whether it's a piece of garbage or not; all I know is that I have a bunch of iPad apps that I've paid for and Apple's ecosystem makes it easy to add another iPad and transfer my settings over.
I have a 2013 Nexus 7, and we just got the $50 Fire for the kids while it was on sale. The Nexus 7, even for the "2013", is still a perfectly credible Android tablet, with "full HD". The $50 Fire is 720P, so the display is noticeably worse, but, that probably actually helps with its performance. Otherwise, that $50 Fire is really only slightly slower than the Nexus 7. I even played some MinecraftPE on the Fire, and it was just fine. I didn't have an FPS meter but it was at least 20-30. (I wouldn't be surprised for battery reasons that the game is capped at 30 anyhow. Given the nature of the game and the input I can't tell if the FPS is going much higher on any of those two devices or my last-year's Moto X, the most powerful Android device I own; not enough action.)
It may not meet a techy's high-end needs, but the $50 is perfectly credible now. Not like a $50 tablet two years ago, which was slow, had an immediately-noticeably-crappy touchscreen, and was latent in everything it did. I suspect Amazon's still subsidizing it a bit even at that price, but probably not that much. Those SoCs are really pushing things along. (Pity they're so proprietary.)
Going off the usual price for apps ($2.99?), and a 'bunch' is probably about 25 apps, then replacing all your paid iOS apps with paid Fire apps would probably cost you $75.
So ignoring anything else, a lot of people would actually value their $75 sunk app costs greater than the $350 difference between that iPad and the Fire. It's a pretty interesting lesson in humanity.
App store availability aside (many apps are available on iOS that are not available on Fire's outdated Android derivative), Android tablet apps are kind of crappy. Apple wouldn't be able to get away with their premium pricing if the experience on Android were better.
Every review of an Android tablet complains about how the software is buggy and the ecosystem isn't there yet. Still. Again, I was never convinced there was a larger market for tablets; just a market for iPads.
I actually looked up the price of this fridge thinking that maybe it wouldn't be that much more than a mini... $3,600 for the current revision of that model, haha.
I guess it sort of is, hOOk, though I'm not sure how to write about my specific experience without it being just that.
Before my app was featured, I was looking online for two pieces of information, how to get featured and how many downloads I could get from being featured.
All I could find for how to get featured was "make a good app", turns out that part is true.
I couldn't find anything for what to expect as a result of being featured. Some people shared general looking graphs, but I'm sharing actual numbers so that people can have an idea of the process, and the result, of being featured.
Pfizer currently has a Lymes vaccine study that I have some personal knowledge on that should be wrapped up in 2025: https://www.pfizer.com/news/press-release/press-release-deta...
> About the VALOR trial VALOR is an ongoing randomized, observer-blind, placebo-controlled Phase 3 trial which has enrolled 9,437* participants 5 years of age and older to receive VLA15 or a saline placebo (1:1 ratio). As part of the primary series, participants receive three doses of VLA15 within the first year at months 0, 2 and 5-9, and one booster dose 9-12 months after completion of the primary immunization.5 The final primary series vaccination for participants occurs just before the peak Lyme disease season for the region. Participants will be followed for the occurrence of Lyme disease. The trial is conducted at sites located in areas where Lyme disease is highly endemic across the U.S., Canada and Europe and has enrolled volunteers with a cleared past infection with Borrelia burgdorferi as well as Borrelia burgdorferi naïve volunteers.